Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984;17(Suppl 1):59S–64S. doi: 10.1111/j.1365-2125.1984.tb02429.x

The effect of cimetidine on the relative cardioselectivity of atenolol and metoprolol in asthmatic patients

M E Ellis, M Hussain, A K Webb, N P Barker, T J Fitzsimons
PMCID: PMC1463253  PMID: 6743475

Abstract

1 The effects of chronic cimetidine therapy on the pharmacodynamic properties of atenolol and metoprolol were assessed in eight asthmatic patients using a placebo-controlled trial.

2 When atenolol and metoprolol were administered at doses which achieved an equivalent degree of β1-adrenoceptor blockade, metoprolol caused a significantly greater reduction in mean forced expiratory volume in one second (FEV1). This demonstrates the greater cardioselectivity of atenolol.

3 The reductions in mean FEV1 induced by either atenolol or metoprolol were each unaffected by cimetidine.

4 Plasma levels of each of the β-adrenoceptor blockers were not affected by the addition of cimetidine.

5 The FEV1 in one patient was further reduced when cimetidine was administered with metoprolol, although there was no corresponding change in plasma levels of drug. In this patient there was no such further reduction in FEV1 with atenolol.

6 This study has not provided evidence for a pharmacodynamic interaction between cimetidine and either atenolol or metoprolol, but further studies are indicated.

Keywords: asthma, atenolol, cimetidine, FEV1, metoprolol

Full text

PDF
59S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ellis M. E., Sahay J. N., Chatterjee S. S., Cruickshank J. M., Ellis S. H. Cardioselectivity of atenolol in asthmatic patients. Eur J Clin Pharmacol. 1981;21(3):173–176. doi: 10.1007/BF00627916. [DOI] [PubMed] [Google Scholar]
  2. Feely J., Wilkinson G. R., Wood A. J. Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med. 1981 Mar 19;304(12):692–695. doi: 10.1056/NEJM198103193041202. [DOI] [PubMed] [Google Scholar]
  3. Harron D. W., Balnave K., Kinney C. D., Wilson R., Russell C. J., Shanks R. G. Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol. Clin Pharmacol Ther. 1981 Mar;29(3):295–302. doi: 10.1038/clpt.1981.39. [DOI] [PubMed] [Google Scholar]
  4. Heagerty A. M., Donovan M. A., Castleden C. M., Pohl J. F., Patel L., Hedges A. Influence of cimetidine on pharmacokinetics of propranolol. Br Med J (Clin Res Ed) 1981 Jun 13;282(6280):1917–1919. doi: 10.1136/bmj.282.6280.1917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Houtzagers J. J., Streurman O., Regårdh C. G. The effect of pretreatment with cimetidine on the bioavailability and disposition of atenolol and metoprolol. Br J Clin Pharmacol. 1982 Jul;14(1):67–72. doi: 10.1111/j.1365-2125.1982.tb04935.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kirch W., Köhler H., Spahn H., Mutschler E. Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet. 1981 Sep 5;2(8245):531–532. doi: 10.1016/s0140-6736(81)90921-1. [DOI] [PubMed] [Google Scholar]
  7. MCNEILL R. S. EFFECT OF A BETA-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICS. Lancet. 1964 Nov 21;2(7369):1101–1102. doi: 10.1016/s0140-6736(64)92617-0. [DOI] [PubMed] [Google Scholar]
  8. Mcainsh J., Simpson W. T., Holmes B. F., Young J., Ellis S. H. Bioavailability of atenolol formulations. Biopharm Drug Dispos. 1980 Oct-Dec;1(6):323–332. doi: 10.1002/bdd.2510010604. [DOI] [PubMed] [Google Scholar]
  9. Melander A., Danielson K., Scherstén B., Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther. 1977 Jul;22(1):108–112. doi: 10.1002/cpt1977221108. [DOI] [PubMed] [Google Scholar]
  10. Reeves P. R., McAinsh J., McIntosh D. A., Winrow M. J. Metabolism of atenolol in man. Xenobiotica. 1978 May;8(5):313–320. doi: 10.3109/00498257809060956. [DOI] [PubMed] [Google Scholar]
  11. Regårdh C. G., Johnsson G. Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet. 1980 Nov-Dec;5(6):557–569. doi: 10.2165/00003088-198005060-00004. [DOI] [PubMed] [Google Scholar]
  12. Regårdh C. G., Johnsson G., Jordö L., Sölvell L. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacol Toxicol (Copenh) 1975;36(Suppl 5):45–58. doi: 10.1111/j.1600-0773.1975.tb03321.x. [DOI] [PubMed] [Google Scholar]
  13. Scales B., Copsey P. B. The gas chromatographic determination of atenolol in biological samples. J Pharm Pharmacol. 1975 Jun;27(6):430–433. doi: 10.1111/j.2042-7158.1975.tb09473.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES